{"name":"Ikena Oncology","slug":"ikena","ticker":"IKNA","exchange":"NASDAQ","domain":"ikenaoncology.com","description":"Ikena Oncology is a biopharmaceutical company focused on the development of novel immunotherapies for the treatment of cancer. The company's pipeline includes several promising candidates, including its lead product, IK-930, which is currently in Phase 2 clinical trials. Ikena Oncology aims to leverage its expertise in immunology and oncology to bring innovative treatments to patients with cancer. With a strong focus on research and development, the company is well-positioned to make a meaningful impact in the oncology market.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Mark Manfredi","sector":"Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":800000,"revenueGrowth":-77.1,"grossMargin":0,"rdSpend":28525000,"netIncome":-45349000,"cash":152976000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2033-06-01","label":"IK-930 patent cliff ($0.0B at risk)","drug":"IK-930","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Ikena Oncology Announces FDA Clearance of IND for IK-930","summary":"Ikena Oncology announced that the FDA has cleared the Investigational New Drug (IND) application for IK-930, enabling the company to proceed with Phase 2 clinical trials.","drugName":"IK-930","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Ikena Oncology Reports Third Quarter 2023 Financial Results","summary":"Ikena Oncology reported its third-quarter 2023 financial results, highlighting progress in its pipeline and strong cash position.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQlJtd0VQdWkzR1NkVUJkUVBIaUdSei1fd2xveVVZeGw3bE00RlBrMWU1SWdDWlZyZVBKRmk0bnBweWQ1aUFmOG5kRVR4b08tX2h6cWZKX1VVVDlnTFlqYWVWMHFPaVZFZGhqZXZxd0NIZUkzSzE5aFVTbGM1T0FyM2VUNUl2WDdLc2swZ2JTMThSeDl3cTNEZTBXNkY2Q1U5NUZxUGt4ZEtOVGQ5UXZzVlhEZWNoNjhRa0xZ?oc=5","date":"2026-01-25","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Ikena Oncology Inc (IKNA): Tiny Biotech, Massive Plot Twist for Your Portfolio - AD HOC NEWS","headline":"The Truth About Ikena Oncology Inc (IKNA): Tiny Biotech, Massive Plot Twist for Your Portfolio","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOVTZ1d2toTTVtazVJYnhLc1hYeXBBZTJ2RlNHUzZuaXB5N1NUUWh6QmRXNXhPWVhaQVNlbDItN0RXNUtNTTk4SVF1dXRyLVpIaEZZcnlXZEd0UjBmOWtlc2VyY2tZQ2pSMFAtYjl1d3pWTnhoSjRBZU00aFNjc1RkdEZoY0RCRFMxRDVFS2RsMjhDTEg0QndIM3dOWDloUDZhTEp3?oc=5","date":"2025-07-25","type":"deal","source":"Yahoo Finance","summary":"Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - Yahoo Finance","headline":"Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxONm4zZlNSVnRBVE1UNnNIWTFPbC1DbUl6ZDBpZFZUUzhoYVRSTWVwOVJHUmFlMEVNd1pNMng3X3JiRnVqWU1SUmtWUnJ6Vlp4OWQtUUZSVERlRTNIcmpfUVZnNEcyTU5LZmJ4YlZzaUNqVjJ2WXVCbGFfWXNrbENfY1hVT29MRFhWYlE1ZXNTc1dWY09rYXBKakFPT2x3WlV3Zzg2OVcxWG45LWJUT01IcWV6UC1BNHlEOTh3Z0Q2QW44WHBud3VkVFZzUUx5YXZKVGFiOHNNRXFkdzNrYkN4cFJmYkdUSFZJTjhDUUgwT2ROUQ?oc=5","date":"2025-07-15","type":"regulatory","source":"globenewswire.com","summary":"Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - globenewswire.com","headline":"Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPNXVOd2F5VF94OE05c3gzbE5zeXcxaENUcFk3di1EelV2NTZ1SnI5ZGZ6RXVfem9lUXRURGktY1dOUXNfdkpCMTZOLW1LNktoemRMWjA4aDR4OUYwQlN6RWljNm5qMXlPcEZSSXJCakVWd0hSc2FHbHU2cHBaN0Vnd1dtWkJ1LVdUVlE3UGtDMV9DWkZoLVVnOW45cFF5dw?oc=5","date":"2025-01-02","type":"pipeline","source":"thebambooworks.com","summary":"Inmagene Bio charts backdoor to U.S. listing with offshore acquisition - thebambooworks.com","headline":"Inmagene Bio charts backdoor to U.S. listing with offshore acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQSmMtcTJ5amFmX1U1UW5EMFRNaVAxdGFLYzJ0MVpodHBtYkZySTJ6c0k2UFhvckRNVWN0cVlwa1hNY1NfT0xubnJieHluR0g3eXNhRG16ZHJCS21jUkJBblhhNVhzQjJKU1pkN3NpM21DU3puZXhiaVc2czN2YUZJWGFEZ2pnVGtxUVdn?oc=5","date":"2024-12-27","type":"pipeline","source":"The Business Journals","summary":"The definitive Boston biotech layoff tracker for 2024 - The Business Journals","headline":"The definitive Boston biotech layoff tracker for 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOOGZma0pUY1JvVzlSbnd2TW1vYm05cXNRa1YzbGhZT1dMMW9RdExidE1wY1Y0VkJsRzl5N0tlb0R6NzhkZ1ZoN29SVVNlVUVYOWxyb3lWOWZkU3pNMW1sOXdoQjNvUTlLYUNMSXVrZFMxbFFrSVdSUnhNMXZUR0N1M0o1TDI2bWl0VkxyZE96bnFEY29BYXdCbVFfSkp1VlRJYVpZYnN1TUFXVmFMYmVLQ0dpY25sVGhVNmRxVnBPRU1rMXVVT1hvU0pmMFo2TGN1aDYxb3RsQ3dldko5dXZRXzQwZm15aHVyZWh3Q0lmWm9QZFEwTFh3VnNGZEhZbVk?oc=5","date":"2024-12-23","type":"deal","source":"globenewswire.com","summary":"Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - globenewswire.com","headline":"Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNSXV3QlF0SmFoZ0JnUk1ZZzl0R0FiUG1MTWFxMUFPUlgxZ2kxTWxiWGszNlh4a052SXp3bXJKbmpySEpXMmd4NGxzTWltQ0hLbzJ3ZUNYdTFMZlAxNHNBQzNRZzdjRTFuZFJNcHRVYy05Zy1MaXhCWXNDN0h4Uk4yVzI0a0lzMHZNdS02X3UtNjFSN0NJT25HU0R6c2hFNVR0SEE?oc=5","date":"2024-04-08","type":"earnings","source":"The Business Journals","summary":"Biotech layoffs tracker: 14 biotechs cut over 300 jobs in Q1 2024 - The Business Journals","headline":"Biotech layoffs tracker: 14 biotechs cut over 300 jobs in Q1 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNd0M3c1pRLWppZ3JZazFPSXVtRUR5c3dQRVJyYjBwUkp2WkVqR1B2QVpSZ0U3cWdTMXlucWx2SEFlTks3cXpOb2hGMlRJb21ZbDJJd0JYSHZJUmZ3M19oU1JMZTV6M1ZMR3dpY1BiQjBhSDdvTXZOOENrbWhtZmI3LXJiOGNseEtyNnc?oc=5","date":"2023-11-09","type":"trial","source":"Seeking Alpha","summary":"Ikena stock falls after data for lead asset, Q3 results - Seeking Alpha","headline":"Ikena stock falls after data for lead asset, Q3 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPNi1FY2dRa1RBTHNhWGFBQk8zS0xvU2swRVF0Q21sWmpEZWhSMzZFc0loUHJ4Ynl6bDBBRDNtSWp1S0Z1clhkNHU0LWNxSTVhWXY0U19ET1NuSjkwczA2SW5RVVU4aGtGdHRYTU5nZExmcmpzNlZtYVZHX1ZyS1czWXpMeF85M0lvUV9rZnZZV08xTlBZenJXZlpSSzBJRnFlR1NpaTU4QkRHOGV1c2ZSbkY0OFZkZmVlNnhmbTlXem1VTGt0MFF3Rw?oc=5","date":"2022-05-03","type":"pipeline","source":"Business Wire","summary":"Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer - Business Wire","headline":"Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer","sentiment":"neutral"}],"patents":[{"drugName":"IK-930","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immunotherapy","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":800000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":800000,"period":"2025-12-31"},{"value":3500000,"period":"2024-12-31"},{"value":9160000,"period":"2023-12-31"},{"value":9160000,"period":"2023-12-31"},{"value":15618000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":28525000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-45349000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":152976000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}